Fadi Eskandar

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Developing therapeutics for the treatment of pediatric asthma
    Fadi Eskandar
    Novartis Pharma AG, Pharmaceutical Development Unit Inhalation, PO Box 4002, Basel, Switzerland
    Curr Opin Investig Drugs 11:550-8. 2010
  2. ncbi Low powder mass filling of dry powder inhalation formulations
    Fadi Eskandar
    Novartis Pharma AG, PDU Inhalation, Basel, Switzerland
    Drug Dev Ind Pharm 37:24-32. 2011

Collaborators

Detail Information

Publications2

  1. ncbi Developing therapeutics for the treatment of pediatric asthma
    Fadi Eskandar
    Novartis Pharma AG, Pharmaceutical Development Unit Inhalation, PO Box 4002, Basel, Switzerland
    Curr Opin Investig Drugs 11:550-8. 2010
    ..Significant effort needs to be invested in the area of pediatric asthma to increase the availability of high-quality, patient-centric medication and delivery systems...
  2. ncbi Low powder mass filling of dry powder inhalation formulations
    Fadi Eskandar
    Novartis Pharma AG, PDU Inhalation, Basel, Switzerland
    Drug Dev Ind Pharm 37:24-32. 2011
    ..This is especially true for dry powder inhaler (DPI) applications where, together with good manufacturability, powders must also exhibit properties that allow acceptable product performance...